{
    "name": "levocetirizine",
    "comment": "OTC",
    "other_names": [
        "Xyzal Allergy 24HR Tablets",
        "Xyzal Allergy 24HR Oral Solution",
        "Xyzal"
    ],
    "classes": [
        "Antihistamines",
        "2nd Generation"
    ],
    "source": "https://reference.medscape.com/drug/xyzal-levocetirizine-343385",
    "pregnancy": {
        "common": [
            "Available data from published literature and postmarketing experience in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by oral route to pregnant rats and rabbits, during period of organogenesis, at doses up to 390 times and 470 times, respectively, maximum recommended human dose (MRHD) in adults",
                    "Rats treated during late gestation and lactation period, had no effects on pup development at oral doses up to approximately 60 times the MRHD in adults; in mice treated during late gestation and lactation period, drug administered by oral route to dams had no effects on pup development at a dose that was approximately 25 times the MRHD in adults; however, lower pup weight gain during lactation was observed at a dose that was 95 times MRHD in adults"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of levocetirizine in human milk, effects on breastfed infant, or on milk production; however, drug has been reported to be present in human breast milk; in mice and beagle dogs, studies indicated cetirizine was excreted in milk; when a drug is present in animal milk, it is likely the drug will be present in human milk; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to levocetirizine or cetirizine",
                "ESRD (CrCl <10 mL/min) or patients undergoing hemodialysis",
                "Children aged 6 month to <12 years with renal impairment"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Caution in narrow angle glaucoma, stenosing peptic ulcer, or pyloroduodenal obstruction",
                "Pruritus may rebound within several days of stopping therapy, following long term use",
                "May cause CNS depression and impair physical or mental abilities; avoid performin tasks that require mental alertness, including operating heavy machinery or driving",
                "Urinary retention may occur; use caution in patients at risk of urinary retention, including prostatic hyperplasia and spinal cord injuries",
                "Use caution in patients with mild to severe renal impairment",
                "Avoid alcohol or other CNS depressants"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid increases effects of levocetirizine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects.  MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "levocetirizine, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "levocetirizine and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine increases effects of levocetirizine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifampridine",
            "description": {
                "common": "levocetirizine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and levocetirizine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "levocetirizine, clobazam. Other (see comment). Use Caution/Monitor. \nComment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "levocetirizine and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "diazepam intranasal, levocetirizine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil transdermal",
            "description": {
                "common": "donepezil transdermal, levocetirizine.\nEither decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, levocetirizine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin, levocetirizine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil, levocetirizine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyaluronidase",
            "description": {
                "common": "levocetirizine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. \nComment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, levocetirizine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, levocetirizine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine increases effects of levocetirizine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "pregabalin, levocetirizine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases levels of levocetirizine by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, levocetirizine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "theophylline",
            "description": {
                "common": "theophylline increases levels of levocetirizine by decreasing elimination. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Severe hypotension",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Cholestasis",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Extrapyramidal symptoms",
            "percent": null
        },
        {
            "name": "myoclonus",
            "percent": null
        },
        {
            "name": "orofacial dyskinesia",
            "percent": null
        },
        {
            "name": "tic",
            "percent": null
        },
        {
            "name": "Pregnancy",
            "percent": null
        },
        {
            "name": "puerperium and perinatal conditions",
            "percent": null
        },
        {
            "name": "Stillbirth",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Glomerulonephritis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "acute generalized exanthematous pustulosis",
            "percent": null
        },
        {
            "name": "AGEP",
            "percent": null
        },
        {
            "name": "rebound pruritus",
            "percent": null
        },
        {
            "name": "pruritus within a few days after discontinuation of cetirizine",
            "percent": null
        },
        {
            "name": "usually after long",
            "percent": null
        },
        {
            "name": "term use",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "months to years",
            "percent": null
        }
    ]
}